CymaBay Therapeutics, Inc.
NASDAQ: CBAY0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sujal A. Shah
- Employees
- 101
- Headquarters
- Newark, United States
- IPO year
- 2014
- Market cap
- $3.7B
- Website
- https://www.cymabay.com
Loading CBAY…
Loading profile data…Frequently asked questions about CBAY
What does CymaBay Therapeutics, Inc. (CBAY) do?
CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses. A key experimental therapy in their portfolio is seladelpar (MBX-8025), a selective activator of the peroxisome proliferator activated receptor de...
Where does CBAY trade?
CymaBay Therapeutics, Inc. (CBAY) trades on the NASDAQ Global Select.
What sector is CBAY in?
CymaBay Therapeutics, Inc. (CBAY) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of CymaBay Therapeutics, Inc.?
Sujal A. Shah is the chief executive officer of CymaBay Therapeutics, Inc. (CBAY).
Where is CymaBay Therapeutics, Inc. headquartered?
CymaBay Therapeutics, Inc. is headquartered in United States.
Does CBAY pay a dividend?
CymaBay Therapeutics, Inc. (CBAY) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CBAY go public?
CymaBay Therapeutics, Inc. (CBAY) completed its initial public offering in 2014.